National Cancer Center

And actually had a considerable difference in overall survival.

Well, recently, our colleagues at the National Cancer Center in Japan had validated this in a large clinical trial that they did prospectively as part of a large screening trial that they have for blood count profiling.

And Shaw saw the significant benefit in using that predictor for determining which patients benefit from platinum therapy versus a rinotecan-based therapy trial.

And right now actually designing a new prospective clinical trial along those spaces for metastatic colorectal cancer.